3-quinuclidinyl heteroatom bridged biaryl derivatives

Details 3-quinuclidinyl heteroatom bridged biaryl derivatives 3-quinuclidinyl heteroatom bridged biaryl derivatives

2007-07-10

2007-07-10

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S183000, C514S299000, C540S471000, C546S133000, C546S135000

Reexamination Certificate

active

11015157

ABSTRACT:
Compounds of formula:or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+—O−; m and n are each independently 0, 1, or 2; X1and X3are each independently O, S, and —N(R1)—; X2is O, S, —N(R1)—, —N(Ar2)—and —N(R2)C(O)—; Ar1is a six-membered aromatic ring; Ar2is cyclohexyl or a mono- or bicyclic aromatic ring, and R13is hydrogen, alkyl, or halogen, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formulas (I) and (II) and methods for using such compounds and compositions.

REFERENCES:
patent: 0 709 381 (1996-05-01), None
patent: 0 774 256 (1996-11-01), None
patent: 0773027 (1997-05-01), None
patent: 92/04333 (1992-03-01), None
patent: 94/18201 (1994-08-01), None
patent: 95/03302 (1995-02-01), None
patent: 96/12711 (1996-05-01), None
patent: 98/27983 (1998-07-01), None
patent: 2004/016608 (2004-02-01), None
patent: 2004/022556 (2004-03-01), None
U.S. Appl. No. 10/744484, filed Dec. 2003, Tao.
Conejo-Garcia, et al., “A prodrug system for hydroxylamines based on esterase catalysis”, Bioorganic and Medicinal Chemistry Letters, 15 (2005), 4004-4009.
Sriram, et., “Synthesis of stavudine amino acid ester prodrugs...”, Bioorganic and Medicinal Chemistry Letters, 14, 2004, 1085-1087.
Bader et al, Journal of Medicinal Chemistry, vol. 12, No. 5, pp. 1108-1109, 1969.
Adler et al, “Schizophrenia, sensory gating, and nicotinic receptors,” Schizophrenia Bulletin 24(2):189-202 (1998).
Cordero-Erausquin et al., “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord,” PNAS 98(5):2803-2807 (2001).
Friedman et al., “A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia,” Biol. Psychiatry 51:349-357 (2002).
Heeschen et al., “Nicotine stimulates angiogenesis and promotes tumor growth and athersclerosis,” Nature Medicine 7(7):833-839 (2001).
Heeschen et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetycholine receptors,” Journal of Clinical Investigation 110(4):527-536 (2002).
Jonnala et al., “Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists,” Journal of Neuroscience Research 66:565-572 (2001).
Kihara et al., “α7 Nicotinic receptor transduces signals to phosphatidylinositol 3- kinase to block A β-amyloid-induced neurotoxicity,” Journal of Biological Chemistry 276(17):13541-13546 (2001).
Leonard et al., “Smoking and schizophrenia: abnormal nicotinic receptor expression,” European Journal of Pharamcology 393:237-242 (2000).
Levin, “Nicotinic receptor subtypes and cognitive function,” J. Neurobiol. 53:633-640 (2002).
Liu et al., “β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons,” PNAS 98(8):4734-4739 (2001).
Rowley et al., Current and novel approaches to the drug treatment of schizophrenia, Journal of Medicinal Chemistry 44(4):477-501 (2001).
Shimohama et al., “Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage,” Brain Research 779:359-363 (1998).
Son et al., “Evidence suggesting that the mouse sperm acrosome reaction initiated by the zona pellucida involves an α7 nicotinic acetylcholine receptor,” Biology of Reproduction 68:1348-1353 (2003).
Stevens et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice,” Psychopharmacology 136:320-327 (1998).
Torii et al., “A versatile cycloaddition for the generation of pyrrolidine derivatives via C-N-C 1,3-dipoles,” Chemistry Letters 747-748 (1996).
Wang et al., “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation,” Nature 421:384-388 (2003).

Affiliated with

Also associated with

Rating

3-quinuclidinyl heteroatom bridged biaryl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-quinuclidinyl heteroatom bridged biaryl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-quinuclidinyl heteroatom bridged biaryl derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3791674